GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » Median PS Value

BioInvent International AB (LTS:0H22) Median PS Value : kr7.17 (As of Dec. 12, 2024)


View and export this data going back to . Start your Free Trial

What is BioInvent International AB Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. BioInvent International AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr0.586. BioInvent International AB's 10-Year median PS Ratio is 12.2355. Therefore, the Median PS Value for today is kr7.17.

As of today (2024-12-12), BioInvent International AB's share price is kr43.925. BioInvent International AB's Median PS Value is kr7.17. Therefore, BioInvent International AB's Price to Median PS Value for today is 6.13.

The historical rank and industry rank for BioInvent International AB's Median PS Value or its related term are showing as below:

LTS:0H22' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54   Med: 1.41   Max: 14.44
Current: 6.13

During the past 13 years, the highest Price to Median PS Value of BioInvent International AB was 14.44. The lowest was 0.54. And the median was 1.41.

LTS:0H22's Price-to-Median-PS-Value is ranked worse than
95.83% of 264 companies
in the Biotechnology industry
Industry Median: 0.7 vs LTS:0H22: 6.13

BioInvent International AB Median PS Value Historical Data

The historical data trend for BioInvent International AB's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Median PS Value Chart

BioInvent International AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.04 38.79 3.12 61.54 11.42

BioInvent International AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.34 11.42 9.60 9.54 7.20

Competitive Comparison of BioInvent International AB's Median PS Value

For the Biotechnology subindustry, BioInvent International AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Price-to-Median-PS-Value falls into.



BioInvent International AB Median PS Value Calculation

BioInvent International AB's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.586*12.2355
=7.17

10-Year Median PS Ratio is 12.2355.
BioInvent International AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.586.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB  (LTS:0H22) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

BioInvent International AB's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=43.925/7.17
=6.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB Median PS Value Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines